Page 128 - Assurance of Sterility for Sensitive Combination Products and Materials
P. 128

112   Assurance of sterility for sensitive combination products and materials


           Example of a sterile packaging validation protocol outline
           –Introduction
           –Objectives
               o  Design validation, process validation, revalidation … indicate what is covered, indicate
                  key questions to be answered
           –Product & process description
               o  Device description and requirements
               o  Packaging specification
               o  Packaging and Product Families
               o  Worst case consideration
               o  Process Workflow
               o  Transportation, distribution and storage environment
           –References
           –Regulatory requirements
           –Test methods
               o  Rational for selection of test methods
               o  Acceptance criteria
               o  Sensitivity for integrity test methods
               o  Test equipment
               o  Validation of test methods
           –Validation Resources
               o  Internal team and responsibilities
               o  Third party test labs support
           –Study Design
               o  Process validation
                       IQ
                       OQ
                       PQ
                       Process control measures
               o  Sterilization
               o  Design validation
                       Stability testing
                       Performance testing
                       Clinical evaluation
           –Data from previous studies
           – Sampling and data handling Procedures
           –Statistics
           –Documentation and test report requirements
           –Quality control and assurance
           –Time line
           – Attachments
          Fig. 5.7  Example of a sterile packaging validation protocol outline.

             Fig. 5.9 shows an alternative approach for a validation workflow as pro-
          posed by the Sterile Barrier Association [90]. Interesting aspects of this ap-
          proach is that it includes the creation of a baseline at time zero. This data can
          be used as a reference to compare to accelerated aging and real-time aging
          data. This is essential to draw final conclusions and for root cause analysis in
          case of problems. Another interesting aspect is that product used for acceler-
          ated aging and real-time aging has been exposed first to  performance testing
   123   124   125   126   127   128   129   130   131   132   133